Jennifer Fox Biography and Net Worth

CFO & Sec. of Nuvation Bio

Ms. Fox joined Nuvation Bio in 2020. She has more than 25 years of experience in healthcare investment banking and has been a lead adviser to life sciences companies on over 125 financing and strategic transactions. She joined the company from Citigroup, where she most recently served as a managing director and Co-Head of North America Healthcare Corporate and Investment Banking Group. Prior to CitiGroup, Ms. Fox held senior positions in investment banking at Deutsche Bank, Bear Stearns, Bank of America and Prudential Securities. She holds B.S. degrees in finance and marketing from Manhattan College.

How do I contact Jennifer A. Fox?: The corporate mailing address for Ms. Fox and other Nuvation Bio executives is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. Nuvation Bio can also be reached via phone at 332-208-6102 and via email at [email protected]. Learn More on Jennifer A. Fox's contact information.
Has Jennifer A. Fox been buying or selling shares of Nuvation Bio?: Jennifer A. Fox has not been actively trading shares of Nuvation Bio during the last ninety days. Learn More on Jennifer A. Fox's trading history.
Who are Nuvation Bio's active insiders?: Nuvation Bio's insider roster includes Jennifer Fox (CFO & Sec. ), David Hung (Founder), and Oleg Nodelman (Director). Learn More on Nuvation Bio's active insiders.
Are insiders buying or selling shares of Nuvation Bio?: During the last year, Nuvation Bio insiders bought shares 4 times. They purchased a total of 696,778 shares worth more than $1,985,500.47. The most recent insider tranaction occured on October, 8th when Director Robert Mashal bought 100,000 shares worth more than $220,000.00. Insiders at Nuvation Bio own 5.1% of the company. Learn More about insider trades at Nuvation Bio.
Information on this page was last updated on 10/8/2024.

Jennifer A. Fox Insider Trading History at Nuvation Bio

Jennifer A. Fox Buying and Selling Activity at Nuvation Bio

Nuvation Bio Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Today's Range

Now: $2.87

$2.84

$2.98

50 Day Range

MA: $2.55

$2.00

$3.07

2 Week Range

Now: $2.87

$1.21

$4.16

Volume

630,701 shs

Average Volume

1,471,810 shs

Market Capitalization

$715.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.